论文部分内容阅读
目的探讨非小细胞肺癌(NSCLC)组织中DNA切除修复交叉互补基因1(ERCC1)的表达与铂类化疗远期疗效之间的关系及其对患者预后的影响。方法应用免疫组化法对63例NSCLC手术切除石蜡包埋病理标本中ERCC1基因表达进行测定,并将患者的化疗疗效和生存资料与上述指标表达进行比较。结果 NSCLC组织中ERCC1阳性表达率为26.9%;pTNM分期、ERCC1表达为影响术后NSCLC预后的独立因素,ERCC1表达阴性者的术后生存优于表达阳性者;ERCC1表达阴性者术后使用铂类药物辅助化疗有延长生存时间的趋势。结论 ERCC1表达与术后生存呈负相关,可作为术后NSCLC生存预测的指标。
Objective To investigate the relationship between the expression of DNA repair and repair cross-complementary gene 1 (ERCC1) in non-small cell lung cancer (NSCLC) tissues and the long-term efficacy of platinum-based chemotherapy and its effect on the prognosis of patients. Methods The expression of ERCC1 gene in paraffin-embedded paraffin embedded specimens of 63 cases of NSCLC was detected by immunohistochemistry. The efficacy of chemotherapy and survival data were compared with those of the above indicators. Results The positive rate of ERCC1 expression in NSCLC tissues was 26.9%. The pTNM stage and ERCC1 expression were independent prognostic factors for postoperative NSCLC. The postoperative survival of patients with negative ERCC1 expression was better than those with positive expression of ERCC1. Drug-assisted chemotherapy has the tendency to prolong survival. Conclusion The expression of ERCC1 is negatively correlated with postoperative survival, which can be used as an indicator of postoperative survival of NSCLC.